Research summary, original research, 2018

Decreased Operator X-Ray Exposure By Optimized Fluoroscopy During Radiofrequency Ablation Of Common Atrial Flutter

Zedira A, Greffier J, Brunet X, Pereira F, Winum PF, Granier M. Diagnostic and interventional imaging. 2018

Read the original paper

In plain language

In 38 atrial flutter ablations, halving the fluoroscopy frame rate to 3.75 frames per second was linked to markedly lower operator eye, body and hand dose rates and lower patient dose, without longer procedures. These are dose measurements, not health outcomes.

At a glance

Type of study
Original research, Prospective cohort study
Who was studied
Electrophysiologists, Patients
Size
n = 38 patients
Summary based on
the abstract

What it found

  • Low-dose fluoroscopy at 3.75 frames per second reduced operator exposure by a mean of 90% compared with standard settings.

    Key figures: mean 90% reduction

  • Operator eye-lens, whole-body and hand skin dose rates were significantly lower in the low-dose group than in the standard-dose group.

    Key figures: eye lens 4.7±2.9 μSv/h; whole body 1.6±1.2 μSv/h; hand 11.1±10.8 μSv/h; P<0.001

  • Patient dose rate was lower with the low-dose setting than with standard or collimated settings.

    Key figures: 0.7±0.4 Gy/h vs 1.7±0.5 Gy/h (standard) and 1.8±0.5 Gy/h (collimated); P<0.01

  • Procedure time did not differ between the three fluoroscopy setting groups.

Limits to keep in mind

Small single-procedure-type sample (38 patients, almost all men) with non-randomized group allocation not described; the abstract contains an apparently contradictory statement about no differences in radiation exposure, and the country is not reported.

How this summary was made

ORSIF prepared this summary with AI assistance from the abstract of the paper. A program then checked that the passage supporting each finding appears word for word in that source. A person has not yet reviewed each summary, so read the original before relying on a number. ORSIF summarizes research and does not endorse any product or company. Report a problem with this summary.

Prepared November 3, 2026.